Main Article Content

Himanshu Mahla
Lalit Kumar
Dr. Navdeep Singh Sidhu
Neeraj Chaturvedi
Manisha Keshav
Shashi Mohan Sharma
Rajeev Bagarhatta
V.V. Agrawal
Dr Shiwani Dadarwal


COVID 19, Pulmonary artery systolic pressure (PASP), Tricuspid annular plane systolic excursion (TAPSE), Transthoracic 2d Echocardiography, CT severity index (CTSI), C- Reactive protein (CRP)


Objectives- To study the Echocardiographic manifestations of covid 19 illness among patients admitted in our facility, Correlate MAPSE, TAPSE, PASP, CRP levels, and CTSI among covid 19 patients with their 28-day outcome as survivors and non-survivors and to look for evidence of residual RV dysfunction and Pulmonary hypertension using TTE after 1 year of follow-up.

Study design- Prospective observational study at various medical wards and ICUs in SMS Medical College and associated hospitals.

Methods- 258 patients with a COVID-19 RT-PCR positive report from a throat or a nasal swab within 72 hours of admission were included in the study. Each patient underwent a complete clinical assessment and routine blood investigations including CRP levels were done. A complete transthoracic echocardiogram was done within 48 hours of admission. Patients also underwent a HRCT chest and CTSI scores were estimated. All patients were followed for a period of 28 days. The MAPSE, TAPSE, PASP, CTSI and CRP levels were then correlated with the outcome of the patient. The survivors again underwent a TTE at 1 year after their recovery from covid-19 illness to look for residual RV dysfunction by TAPSE and the development of pulmonary hypertension as measured by PASP using Bernoulli’s equation.

Results-Amongst patient of covid 19 illness the MAPSE, TAPSE, PASP, CTSI and CRP levels all correlated well with outcome of patients. While most covid-19 survivors recovered from their illness yet some patients showed evidence of persistent RV dysfunction and pulmonary hypertension even after 1 year of follow up

Abstract 74 | pdf Downloads 25


1. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. March 30, 2020.
2. Zhou F, Yu T, Du R, Fan G et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054-1062.
3. Guo T, Fan Y, Chen M, Wu X et.al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019(COVID-19). JAMA Cardiol. March 27, 2020.
4. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. (2003) 289:2801–9.
5. Guo T, Fan Y, Chen M, Wu X et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) 5:811–8.
6. Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: Implications for the cardiovascular system. Circulation. (2020) 142:68–78.
7. Wang D, Hu B, Hu C, Zhu F et.al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069.
8. Shi Y, Wang Y, Shao C, Huang J et.al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 May;27(5):1451-1454.
9. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-1800.
10. Dominguez-Erquicia P, Dobarro D, Raposeiras-Roubín S, Bastos-Fernandez G, Iñiguez-Romo A. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. Eur Heart J. 2020 Jun 07;41(22):2132
11. Lang RM, Badano LP, Mor-Avi V, Afilalo J et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28:1-39.e14.
12. Yancy CW, Jessup M, Bozkurt B, Butler J et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128:1810-1852.
13. P. Goyal, J.J. Choi, L.C. Pinheiro, et al. Clinical characteristics of Covid-19 in New York City N Engl J Med: 382 (2020), pg. 2372-2374
14. Gawalko M et.al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications.Int J Cardiol Heart Vasc. 2020; 30: 100631
15. Potus, F.; Mai, V.; Lebret, M.; Malenfant, S.; Breton-Gagnon, E.; Lajoie, A.C.; Boucherat, O.; Bonnet, S.; Provencher, S. Review: The pathophysiology of COVID-19 and SARS-CoV-2 infection novel insights on the pulmonary vascular consequences of COVID-19
16. Van Dongen, C.; Janssen, M.; van der Horst, R.; van Kraaij, D.; Peeters, R.; van den Toom, L.; Mostard, R. Unusually rapid development of pulmonary hypertension and right ventricular failure after COVID-19 pneumonia. EJCRiM 2020, 7, 001784
17. Pagnesi M, Baldetti L, Beneduce A, Calvo F, Gramegna M, Pazzanese V, Ingallina G, Napolano A, Finazzi R, Ruggeri A, Ajello S, Melisurgo G, Camici PG, Scarpellini P, Tresoldi M, Landoni G, Ciceri F, Scandroglio AM, Agricola E, Cappelletti AM. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020 Sep;106(17):1324-1331
18. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation. 2020 Jul 28;142(4):342-353
19. Marc R Dweck, Anda Bularga, Rebecca T Hahn, Rong Bing et.al. Global evaluation of echocardiography in patients with COVID-19, European Heart Journal - Cardiovascular Imaging, Volume 21, Issue 9, September 2020, Pages 949–958
20. Perazzo H et.al.; RECOVER-SUS Brasil Group. In-hospital mortality and severe outcomes after hospital discharge due to COVID-19: A prospective multicenter study from Brazil. Lancet Reg Health Am. 2022 Jul;11:100244.